The following summarizes the report contents by section:
SECTION I: Market Status, Trends and Forecasts
Analysis of current and emerging markets for therapeutic radiopharmaceuticals. Discussion of market prospects by product group and disease category. Review of new products in the pipeline, projections for FDA approval and sales forecasts in all categories to 2012. This includes:
- Analysis of market prospects for new targeted radiotherapy agents that have been approved or in development. Applications include lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer, myeloma, endocrine cancer and other cancers resistant to traditional therapies.
- Projections for new products using novel targeting technologies for treating bone cancer, brain cancer, pancreatic cancer, breast cancer and other cancers that may benefit from these modalities.
- Prospects for new radiotherapies employing isotopes optimized for the application with reduced damage to bystander cells, including lutetium-177, holmium-166, rhenium-188, promethium 149, bismuth 213, bismuth 212, astatine-211 and polonium 210.
- Discussion of product pricing, competitive factors and potential return on investment.
SECTION II: Analysis of Procedure Volume
- Discussion of incidence of disease and relationship to potential radiotherapy procedures. Forecast procedure volume by disease category from 2005-2012 with discussion of rationale for these projections.
- Methodology for collecting procedure data and forecasting future growth. Evaluation of different data sources with rationale for interpreting the results.
SECTION III: Radiopharmaceutical Products and Technology
- Technical principles and functional characteristics of therapeutic radiopharmaceuticals.
- New options in selecting therapeutic isotopes for specific applications.
SECTION IV: Current Developments and Emerging Technologies
- Discussion of new therapeutic radiopharmaceuticals in development, with analysis of technological prospects and potential applications.
- Analysis of product characteristics, performance benefits and trade-offs relative to various therapeutic applications.
SECTION V: End-User Analysis
- Analysis of end-user groups and comparative requirements for radiotherapy products.
- Procedure mix and product utilization in hospitals and clinics.
SECTION VI: Company Profiles
- Background information on companies in the field and review of recent performance.
- Discussion of each company's market activities and management strategies.
|
Back to Top
BTSI230.doc
-OR-
BTSI230.pdf
Send
this page to a friend